Spero M&A Tuesday, July 14, 2026 +0.90 Positive

Spero Therapeutics Licenses Anti-CD40L Antibody SP001 to Innovent

Spero Therapeutics entered into a global license agreement for the anti-CD40L antibody SP001 with Innovent Biologics. The deal potentially worth $1.1 billion aims to expand Spero's pipeline into autoimmune diseases.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day